By 52 Weeks of Treatment (SINUS-52), DUPIXENT Demonstrated1:

-1.34
IMPROVEMENT
IN NC SCORE

LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -1.13 (95% CI: -1.49, -0.77) (-1.34 from a baseline score of 2.38 vs -0.21 from a baseline score of 2.49, respectively).1

-2.54
IMPROVEMENT
IN NPS

LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -2.57 (95% CI: -3.27, -1.87) (-2.54 from a baseline score of 5.87 vs 0.03 from a baseline score of 6.06, respectively).1

-7.27
IMPROVEMENT
IN LMK-CT SCORE

LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -6.86 (95% CI: -8.62, -5.10) (-7.27 from a baseline score of 19.71 vs -0.41 from a baseline score of 19.07, respectively).1

Analysis was not multiplicity controlled; results are descriptive.1


27% of patients enrolled in SINUS-52 presented with NSAID-ERD2

Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.2

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0-4 for each nostril, range 0-8 in total) as evaluated by nasal
endoscopy: reduced score indicates improvement.2

Lund-Mackay computed tomography (LMK-CT) score (range 0-24): reduced score indicates improvement.2

INCS, intranasal corticosteroid; LSM, least squares mean; NSAID-ERD, nonsteroidal anti-inflammatory drug–exacerbated respiratory
disease; Q2W, once every 2 weeks.

SEE SAFETY DATA
BACK TO SNOT-22 RESULTS